Literature DB >> 20478577

Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma.

Tobias Klatte1, Mesut Remzi, Richard E Zigeuner, Sebastian Mannweiler, Jonathan W Said, Fairooz F Kabbinavar, Andrea Haitel, Matthias Waldert, Michela de Martino, Michael Marberger, Arie S Belldegrun, Allan J Pantuck.   

Abstract

PURPOSE: We developed and externally validated a prognostic nomogram specifically for papillary renal cell carcinoma.
MATERIALS AND METHODS: We retrospectively studied 435 patients who underwent radical or partial nephrectomy for papillary renal cell carcinoma at 3 institutions. Slides were reviewed by 1 uropathologist per institution. We constructed a nomogram predicting 5-year disease specific survival as a graphic representation of significant variables on multivariate Cox proportional hazards regression analysis using data on 258 patients from 2 of the 3 institutions. Nomogram discrimination and calibration were assessed by bootstrapping to obtain relatively unbiased estimates. External validation was done in 177 patients from a third institution.
RESULTS: At a median 50.8-month followup 77 papillary renal cell carcinoma related deaths had occurred. In the multivariate Cox proportional hazards model incidental detection, T classification, M classification, vascular invasion and tumor necrosis extent were retained as independent prognostic factors of disease specific survival and formed the basis of the nomogram. The nomogram predicted well with a 93.6% bootstrapped corrected concordance index and showed good calibration. External independent validation revealed 94.2% predictive accuracy.
CONCLUSIONS: We developed a highly accurate tool specifically for papillary renal cell carcinoma using basic clinical and pathological information to predict disease specific survival. This tool should be helpful to identify papillary renal cell carcinoma with aggressive clinical behavior and may contribute to the ability to individualize postoperative surveillance and therapy. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20478577     DOI: 10.1016/j.juro.2010.03.026

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma.

Authors:  Reza Mehrazin; Robert G Uzzo; Alexander Kutikov; Karen Ruth; Jeffrey J Tomaszewski; Essel Dulaimi; Serge Ginzburg; Philip H Abbosh; Timothy Ito; Anthony T Corcoran; David Y T Chen; Marc C Smaldone; Tahseen Al-Saleem
Journal:  Urol Oncol       Date:  2014-07-11       Impact factor: 3.498

2.  External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database.

Authors:  Stefan Zastrow; Laura-Maria Krabbe; Ingmar Wolff; Umberto Capitanio; Tobias Klatte; Thorsten Ecke; Nina Huck; Hendrik Borgmann; Anna Scavuzzo; Luca Cindolo; Luigi Schips; Cristian Surcel; Cristian Mirvald; Antoni Vilaseca Cabo; Mireia Musquera; Georg Hutterer; Kristyna Prochazkova; Christian Stief; Manfred Wirth; Matthias May; Sabine Brookman-May
Journal:  Int J Clin Oncol       Date:  2019-08-30       Impact factor: 3.402

3.  Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.

Authors:  Alcides Chaux; Luciana Schultz; Roula Albadine; Jessica Hicks; Jenny J Kim; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Hum Pathol       Date:  2012-04-26       Impact factor: 3.466

4.  Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery.

Authors:  Rodrigo A Ledezma; Edris Negron; Gladell P Paner; Chris Rjepaj; Danny Lascano; Mohammed Haseebuddin; Pankaj Dangle; Arieh L Shalhav; Henry Crist; Jay D Raman; G Joel DeCastro; Lara Harik; Monika Paroder; Robert G Uzzo; Alexander Kutikov; Scott E Eggener
Journal:  World J Urol       Date:  2015-09-25       Impact factor: 4.226

Review 5.  Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.

Authors:  Theodore F Logan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

6.  The first competing risk survival nomogram in patients with papillary renal cell carcinoma.

Authors:  Xing Su; Niu-Niu Hou; Li-Jun Yang; Peng-Xiao Li; Xiao-Jian Yang; Guang-Dong Hou; Xue-Lin Gao; Shuai-Jun Ma; Fan Guo; Rui Zhang; Wu-He Zhang; Wei-Jun Qin; Fu-Li Wang
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

7.  The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.

Authors:  Tobias Klatte; Kevin M Gallagher; Luca Afferi; Alessandro Volpe; Nils Kroeger; Silvia Ribback; Alan McNeill; Antony C P Riddick; James N Armitage; Tevita F 'Aho; Tim Eisen; Kate Fife; Axel Bex; Allan J Pantuck; Grant D Stewart
Journal:  BMC Med       Date:  2019-10-03       Impact factor: 8.775

8.  Prognostic models in papillary renal cell carcinoma.

Authors:  Kyrollis Attalla; Martin H Voss; A Ari Hakimi
Journal:  Ann Transl Med       Date:  2020-11

9.  Prognostic factors of overall survival in renal cancer patients - single oncological center study.

Authors:  Tomasz Drewniak; Marek Sandheim; Jacek Jakubowski; Kajetan Juszczak; Andrzej Wojciech Stelmach
Journal:  Cent European J Urol       Date:  2013-11-18

10.  Predictive value of preoperative neutrophil-to-lymphocyte ratio in non-metastatic papillary renal cell carcinoma patients after receiving curative surgery.

Authors:  Xiang Tu; Fan Wang; Tiancong Chang; Chichen Zhang; Mengni Zhang; Zhenhua Liu; Shi Qiu; Lu Yang; Qiang Wei
Journal:  Cancer Manag Res       Date:  2019-08-07       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.